369 related articles for article (PubMed ID: 24896823)
1. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
[TBL] [Abstract][Full Text] [Related]
2. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
3. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
4. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
5. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
6. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
[TBL] [Abstract][Full Text] [Related]
7. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.
Décaillot FM; Kazmi MA; Lin Y; Ray-Saha S; Sakmar TP; Sachdev P
J Biol Chem; 2011 Sep; 286(37):32188-97. PubMed ID: 21730065
[TBL] [Abstract][Full Text] [Related]
8. AMD3100 is a CXCR7 ligand with allosteric agonist properties.
Kalatskaya I; Berchiche YA; Gravel S; Limberg BJ; Rosenbaum JS; Heveker N
Mol Pharmacol; 2009 May; 75(5):1240-7. PubMed ID: 19255243
[TBL] [Abstract][Full Text] [Related]
9. CXCR7 as a novel therapeutic target for advanced prostate cancer.
Gritsina G; Yu J
Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058
[TBL] [Abstract][Full Text] [Related]
10. CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.
Torossian F; Anginot A; Chabanon A; Clay D; Guerton B; Desterke C; Boutin L; Marullo S; Scott MG; Lataillade JJ; Le Bousse-Kerdilès MC
Blood; 2014 Jan; 123(2):191-202. PubMed ID: 24277075
[TBL] [Abstract][Full Text] [Related]
11. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
12. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.
Zieger-Naumann K; Kuhl F; Engele J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418
[TBL] [Abstract][Full Text] [Related]
13. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
Odemis V; Lipfert J; Kraft R; Hajek P; Abraham G; Hattermann K; Mentlein R; Engele J
Glia; 2012 Mar; 60(3):372-81. PubMed ID: 22083878
[TBL] [Abstract][Full Text] [Related]
14. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
15. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
16. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
17. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
[TBL] [Abstract][Full Text] [Related]
18. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
19. Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.
Oishi S; Kuroyanagi T; Kubo T; Montpas N; Yoshikawa Y; Misu R; Kobayashi Y; Ohno H; Heveker N; Furuya T; Fujii N
J Med Chem; 2015 Jul; 58(13):5218-25. PubMed ID: 26042340
[TBL] [Abstract][Full Text] [Related]
20. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
